Background Epstein-Barr virus (EBV) was the first human virus identified to express microRNA (miRNA). To date, 44 mature miRNAs are encoded for within the EBV genome. EBV miRNAs have not been profiled in paediatric renal transplant recipients. In this study, we investigated circulating EBV miRNA profiles as novel biomarkers in paediatric renal transplant patients. Methods Forty-two microRNAs encoded within 2 EBV open reading frames (BART and BHRF) were examined in renal transplant recipients who resolved EBV infection (REI) or maintained chronic high viral loads (CHL), and in non-transplant patients with acute infectious mononucleosis (IM). Results Plasma EBV-miR-BART2-5p was present in higher numbers of IM (7/8) and CHL (7/10) compared to REI (7/12) patients. A trend was observed between the numbers of plasma EBV miRNAs expressed and EBV viral load (p < 0.07). Several EBV-miRs including BART7-3p, 15, 9-3p, 11-3p, 1-3p and 3-3p were detected in IM and CHL patients only. The lytic EBV-miRs, BHRF1-2-3p and 1-1, indicating active viral replication, were detected in IM patients only. One CHL patient developed post-transplant lymphoproliferative disease (PTLD) after several years and analysis of 10 samples over a 30-month period showed an average 24-fold higher change in plasma EBV-miR-BART2-5p compared to the CHL group and 110-fold higher change compared to the REI group. Conclusions Our results suggest that EBV-miR-BART2-5p, which targets the stress-induced immune ligand MICB to escape recognition and elimination by NK cells, may have a role in sustaining high EBV viral loads in CHL paediatric kidney transplant recipients.
Introduction
Epstein-Barr virus (EBV) infection is the causative agent of infectious mononucleosis (IM) and is associated with post-transplant lymphoproliferative disease (PTLD) in renal transplant recipients. Current strategies to identify patients at risk of EBV complications utilize surveillance by EBV viral load monitoring. Significant changes in EBV DNA load over time are used to assess the efficacy of antiviral therapy and are also used widely to predict or to detect EBV-associated disorders [1] [2] [3] [4] [5] . A critical limitation is that it is impossible to distinguish EBV DNA from the latent EBV reservoir from virions being produced actively by infected cells. Hence, quantitation of EBV DNA from whole blood alone may be viewed as having a limited role in informing on patient management in different clinical contexts [6] . This is highlighted by the observation that renal transplant recipients both with chronically high EBV viral loads and those who resolve EBV infection can remain clinically well [7] .
MicroRNAs (miRNAs) are a subset of 18-25 nucleotides of non-coding RNAs which negatively regulate gene expression by targeting complementary sequences in messenger RNAs [8] . They have been demonstrated to play key roles in growth and development, regulation of immunity, cell differentiation, metabolism, apoptosis, cell proliferation, and malignant transformation and their function has been linked to certain human diseases [9] [10] [11] . EBV was the first human virus identified to express miRNAs [12] . To date, 44 mature miRNAs are encoded for within the EBV genome, of which 4 miRNAs are derived from the BamH1 fragment H rightward open reading frame 1 (BHRF1), and the remaining 40 are encoded by the BamH1A region rightward transcript (BART) [13] . The potential for EBV miRNAs as biomarkers for monitoring nasopharyngeal carcinoma [14, 15] in paediatric liver transplant recipients [16] and chronic active EBV infection [17] has recently been reported. However, EBV miRNAs have not been profiled in paediatric renal transplant recipients. In this study, the profiles of 42 EBV miRNAs were investigated and compared in paediatric renal transplant patients between those who resolved EBV infection (REI) and those who maintained chronically high EBV viral loads (CHL). Differential plasma EBV miRNA expression in non-transplant individuals with IM was also studied.
Materials and methods

Patients and clinical samples
Paediatric transplant recipients who underwent renal transplantation at the Children's University Hospital Temple Street, Dublin, Ireland between 2007 and 2010 were included in the study (n = 22). Briefly, the primary diseases were renal dysplasia, juvenile nephronophthisis, branchiootorenal syndrome, posterior urethral valves, cystinosis, mitochondrial cytopathy, membranoproliferative glomerulonephritis, focal segmental glomerular sclerosis, anephrosis, Mainzer-Saldino syndrome, and primary oxalosis. One patient was undiagnosed. Ethical approval for the study was obtained from the Research Ethics Committees at the Children's University Hospital and University College Dublin (LS-E-14-65-Dean-Hassan).
Samples were collected prospectively post-transplant according to the protocol set out by the Children's University Hospital. Samples were taken for EBV viral load measurements weekly for the first 3 months, then fortnightly for the next 3 months and then monthly for the following 6 months and then at annual review clinics. If a patient became symptomatic for EBV infection, irrespective of their followup schedule, samples were taken weekly until EBV DNA became undetectable in two consecutive samples. EBV viral load was determined in whole blood using quantitative realtime polymerase chain reaction (qPCR).
CHL patients (n = 10) were defined as those who maintained EBV loads > 5000 copies/tml in whole blood for a minimum period of 6 months post primary infection or reactivation of infection. REI patients were classified as those who experienced primary infection post-transplant or a reactivation of an existing infection but who resolved infection, and did not have a detectable viral load for more than 6 months (n = 12). Demographic characteristics of the patient groups including age at transplant and EBV serostatus pretransplant have been previously published [7] .
The standard immunosuppressive regimen consisted of basiliximab induction, tacrolimus, prednisolone, azathioprine or mycophenolate. Target tacrolimus trough levels in plasma were 12-15 ng/ml for the first 8 weeks after transplant, 8-10 ng/ml for the first year and < 6 ng/ml after the first year. Mycophenolate and azathioprine were stopped when a patient who had detectable EBV DNA developed clinical symptoms or the viral load increased to more than log10 5 copies/ml. Thereafter there was a marked improvement in the majority of patients.
A cohort of non-transplant individuals with IM (n = 8) was included in the study.
Nucleic acid extraction
Commercially available MagNA Pure 96 DNA and Viral nucleic acids (NA) Small Volume kits were used in combination with the MagNA Pure 96 System (Roche, Mannheim, Germany) for the isolation of EBV DNA from 200 µl whole blood or plasma for in vitro diagnostic purposes. The nucleic acid isolation procedure was performed according to the manufacturer's instructions. Briefly, the sample was lysed and the nucleic acids released were denatured. The nucleic acids binding to the silica surface of the added MagNA Pure magnetic glass particles (MGPs) were magnetically separated from the residual lysed sample and unbound substances. The purified nucleic acids were then eluted in a volume of 100 µl.
Quantification of EBV DNA
The Artus ® EBV TM PCR Kit, a ready-to-use system for the in vitro quantitation of EBV DNA (Qiagen GmbH, Hilden, Germany) using the ABI Prism (Taqman) 7500 Analyser, was used in accordance with manufacturer's instruction. This kit contains reagents and enzymes for the specific amplification of a 97 bp (bp) region of the EBV genome and provides 4 standards and an internal Quality Control which is used to prevent misinterpretation of false negative results caused by inhibition of the amplification process or an ineffective nucleic acid extraction. Base matrix was used as the negative control. For standardization of quantitative EBV DNA detection, a positive control containing EBV DNA at 17,780 copies/ml (Acrometrix, Thermo Fisher Scientific, Ireland), was included in every run. EBV DNA was reported as copies/ml and in log values and the lower limit of detection of the assay was 500 copies/ml. External monitoring of EBV DNA quantitationwas through participation in the Quality Control for Molecular Diagnostics scheme.
miRNA isolation
Total RNA was extracted from plasma using the miR-CURY™ RNA isolation kit -biofluids (Exiqon, Vedbaek, Denmark). Plasma was thawed on ice and centrifuged at 3000×g for 5 min in a 4 °C microcentrifuge. An aliquot of 200 μl of plasma per sample was transferred to a new microcentrifuge tube and 60 μl of lysis solution BF containing 1 μg carrier-RNA per 60 μl lysis solution BF and RNA spike-in template mixture (UniSp2 and UniSp4) was added to the sample. The tube was vortexed and incubated for 3 min at room temperature, followed by the addition of 20 μl protein precipitation solution BF. The tube was vortexed, incubated for 1 min at room temperature and centrifuged at 11,000×g for 3 min. The clear supernatant was transferred to a new collection tube, and 270 μl isopropanol was added. The solutions were vortexed and transfer to a binding column. The column was incubated for 2 min at room temperature, and emptied using a vacuum-manifold. Then, 100 μl wash solution 1 BF was added to the columns. The liquid was removed using a vacuum-manifold, and 700 μl wash solution 2 BF was added. The liquid was removed using a vacuum-manifold. 250 μl wash solution was added and the column was spun at 11,000×g to dry the columns entirely. The dry columns were transferred to a new collection tube and 50 μl RNase free H 2 O was added directly on the membrane of the spin column. The column was incubated for 1 min at room temperature prior to centrifugation at 11,000×g. The RNA was stored at − 80 °C.
cDNA synthesis and real-time qPCR
Expression levels of 42 EBV miRNAs with 95% coverage of the EBV genome, encoded within 2 EBV open reading frames (BART and BHRF), and 4 human miRNAs (hsa-miR-16-5p, hsa-miR-103a-3p, hsa-miR-423-5p and hsa-miR-30c-5p) were determined using miRCURY LNA™ Universal reverse transcription (RT) microRNA PCR analysis (Exiqon, Denmark). Briefly, 2 µl RNA was reverse transcribed in 10 μl reactions using the miRCURY LNA™ Universal RT microRNA PCR, Polyadenylation and cDNA synthesis kit (Exiqon). Each RT was performed in duplicates, including an artificial RNA spike-in (UniSp6).
cDNA was diluted 50 x and assayed in 10 ul PCR reactions according to the protocol for miRCURY LNA™ Universal RT microRNA PCR; each microRNA was assayed once by qPCR using assays for miR-23a, miR-30c, miR-103, miR-142-3p, and miR-451. In addition to these miRNA assays, the RNA spike-ins were assayed. Negative controls excluding template from the reverse transcription reaction were performed and profiled like the samples. The amplification was performed in a LightCycler ® 480 Real-Time PCR System (Roche, Germany) in 384 well plates. The amplification curves were analyzed using the Roche LC software, both for determination of the 2nd -derivative crossing point (Cp) and for melting curve analysis.
Data analysis
The raw data were extracted from the Lightcycler 480 software. An average Cp was calculated for the duplicate RTs, and evaluation of expression levels was performed based on raw Cp values. The average expression level of the above 4 human miRNAs which were identified in all plasma samples, was used to normalize the remaining data.
Statistical analysis
Differential expression of miRNAs was compared using Student's t-test with Benjamini-Hochberg correction. Mann-Whitney U test was used to compare patient cohorts. The association between 2 variables was assessed by Spearman rank correlation coefficient (r). A value of p < 0.05 was considered statistically significant.
Results
Considerable variation was observed in both the number of EBV miRNAs detected (ranging from 0 to 17) and in their average relative expression levels as shown in the heat maps in Fig. 1 . In the three study cohorts examined, most EBV miRNAs were detected in the IM group (7.25 on average), followed by CHL (3.7) and REI (1.9). EBV-miR-BART2-5p and EBV-miR-BHRF1-2-5p were detected most frequently in the patient cohorts. Plasma EBV-miR-BART2-5p was present in higher numbers of IM (7/8) and CHL (7/10) patients compared to REI (7/12). However, there was no significant difference in the relative levels of expression of either EBV miRNA, when comparing REI with CHL, or either transplant group with the IM cohort. Only four other EBV miRNAs were detected in any of the REI samples (BART5-5p, 6-3p, 6-5p and 12). Of note, 3 EBV miRNAs (BART5-5p, 6-5p and 12) were observed in the REI and CHL cohorts only. In contrast, both the IM and CHL groups showed expression of a much broader range of miRNAs, with: 25 in total, 9 of which were common to both (BART1-3p, 3-3p, 6-3p, 7-3p, 9-3p, 11-3p, 13-3p, 15, and 19-3p). Plasma EBVmiR-BHRF1-2-5p was present in higher numbers of REI (11/12) and IM (6/8) compared to CHL (5/10) patients.
Interestingly, the lytic EBV-miRs, BHRF1-2-3p and 1-1, indicating active viral replication, were detected in IM patients only. A trend albeit not significant (p < 0.07) was observed between EBV viral load and the number of EBV miRNAs expressed in 15 plasma samples (Fig. 2) . Viral loads were not available in the remaining samples.
Seventeen distinct EBV miRNAs were detected during the analysis of 10 samples over a 30-month period from a patient in whom PTLD was clinically diagnosed and who subsequently clinically improved (Fig. 3) . The levels and numbers of EBV miRNAs peaked at the time of PTLD diagnosis. BHRF1-2-5p appeared, albeit at low levels, 5 months prior to development of PTLD and remained detectable for 9 months post-PTLD diagnosis. Several other miRNAs including BART14-3p, 17-3p, 3-3p, 5-3p, 6-5p, 8-3p, 6-3p, 21-5p, 9-3p and 7-3p were detectable at the time of PTLD diagnosis. Although not significant, a trend was observed between EBV viral load and the number of EBV miRNAs expressed in this patient over the 10 time points studied (p = 0.058).
As with the other cohorts studied, the BART2-5p and BHRF1-2-5p miRNAs were most commonly detected, and represented the highest and lowest relative expression levels, respectively. Comparing these longitudinal samples with the other study cohort samples, the patient who developed PTLD demonstrated an average 24-fold higher level of plasma EBV-miR-BART2-5p compared to the CHL group (p < 0.003), 38-fold higher compared to the IM group (p < 0.02) and 110-fold higher compared to the REI group (p < 0.001).
Principal component analysis (PCA) was performed including the top 7 microRNAs that had the largest variation across all samples. An overview of how the samples clustered based on this variance is shown in Fig. 4 . Apart from the time series samples (TP01-TP10), the data showed no clear clustering of groups and no outliers were detected.
Discussion
Epstein-Barr virus (EBV) is associated with significant complications in the post-transplant setting due to the administration of immunosuppressive therapy to prevent rejection. As a result, the patient's immune response is unable to control virus infection and replication. The greatest risk associated with EBV infection is the development of PTLD, which is associated with a high risk of morbidity and mortality [18] . Biomarkers utilised to diagnose PTLD and predicting long-term outcomes are needed to improve clinical decision-making following kidney transplantation. To date, monitoring of EBV DNA loads in whole blood, plasma and peripheral blood mononuclear cells from this cohort has been routinely employed to facilitate the diagnosis and management of EBV infection and EBV-associated PTLD. However, recent studies from our laboratory and others have demonstrated a number of transplant recipients with chronically high EBV viral loads, thereby calling into question the utility of monitoring EBV viral loads [7] .
The current study represents the first comprehensive clinical investigation of plasma EBV miRNA expression as potential biomarkers for paediatric renal transplant recipients at risk of developing PTLD. Our findings show that although broad variation can be seen in the profile of EBV miRNA expression, the numbers and levels of expression of many of the 42 EBV miRNAs studied were greater in IM and CHL patients than the REI cohort. In 15 plasma samples where EBV viral load was available, a trend although not significant (p < 0.07) was observed between EBV viral load and the number of EBV miRNAs expressed.
The two most commonly detected EBV miRNAs in our study cohorts were EBV-miR-BART2-5p and BHRF1-2-5p miRNAs. EBV-miR-BART2-5p has been reported to target the lytic viral DNA polymerase encoded by BALF5 and has also been shown to influence the innate immune response by downregulating expression of MICB, a natural killer cell ligand which contributes to immune evasion [19, 20] . It is not surprising therefore that BART2-5p was detected in 87.5% of IM, 70% of CHL and 58.3% of REI patients. The dramatically higher relative expression levels of EBVmiR-BART2-5p seen in the renal transplant recipient who developed PTLD may indicate that monitoring BART2-5p expression, alongside other EBV miRNAs and/or "traditional" markers of latent and lytic EBV infection, could provide an important clinical marker in the diagnosis of this disorder. Interestingly, once PTLD developed, expression of BART2-5p disappeared.
Although variable, BHRF1-2-5p was present in 75% of IM, 50% of CHL and 91.7% of REI patients. Of interest, in the patient who developed PTLD, BHRF1-2-5p expression appeared at about 5 months prior to PTLD development and disappeared 6 months post PTLD diagnosis. The BHRF1 cluster is believed to be involved in malignant transformation [21] . Other reports have shown that BHRF1 miRNA facilitates progressive growth, in vitro transformation of infected cells and acute systemic EBV infection [22, 23] . Furthermore, BHRF1 has been shown to prevent primary B cells from apoptosis [24] . In agreement with these findings, in the current study, the lytic EBV-miRs, BHRF1-2-3p and 1-1, indicating active viral replication, were detected in IM patients only. Of note, a study has reported that while interrogating high confidence targets for BHRF1-1, several cellular 3′ UTR clusters could be assigned to both BHRF1-1 and BART4 due to off-set seed homology between these two miRNAs [25] . In the current study, one IM patient expressed BART4-3p and 4-5p supporting the idea that not all EBV miRNAs are expressed throughout all stages of latency; this may be a mechanism which allows EBV to ensure that important cellular transcripts are downregulated [26] .
Other studies and our findings highlight the important functional roles of EBV miRNAs during the viral life cycle including immune evasion, cell survival and proliferation as well as control of the latent/lytic switch. Our results suggest that EBV-miR-BART2-5p, which targets the stress-induced immune ligand MICB to escape recognition and elimination by NK cells, may contribute to the sustained high EBV viral loads in a group of chronic high viral load kidney transplant recipients. Furthermore, the expression of miR-BHRF1-2-5p which correlates with the involvement of BHRF1 mRNAs cluster in cell transformation should be monitored as well. Future investigation in a larger cohort of patients is required to provide additional data to assess the role of EBV miRNAs in the development of malignant EBV complications in transplanted patients and to evaluate their detection as biomarkers for latent and lytic EBV infection.
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